Abstract
Patients with completely resected non-small-cell lung cancer (NSCLC) are subjects for postoperative adjuvant treatment. Recently, several randomized trials with a large number of enrolled patients have shown that platinum-based chemotherapy has potential for improving survival among patients with completely resected NSCLC in Western countries. In Japan, uracil-tegafur was also shown to improve survival among patients with completely resected stage I adenocarcinoma. This review evaluated the role of adjuvant chemotherapy, based on the results of randomized trials and meta-analyses.
| Original language | English |
|---|---|
| Pages (from-to) | 765-769 |
| Number of pages | 5 |
| Journal | Gan to kagaku ryoho. Cancer & chemotherapy |
| Volume | 32 |
| Issue number | 6 |
| Publication status | Published - Jun 2005 |
| Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
